

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ARGENTUM PHARMACEUTICALS LLC

Petitioner

v.

CIPLA LIMITED

Patent Owner

---

Case No. IPR2017-00807

U.S. Patent No. 8,168,620

---

**CIPLA LIMITED'S UPDATED MANDATORY NOTICES**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

## Cipla Limited's Updated Mandatory Notices

Patent Owner, Cipla Limited, hereby files updated mandatory notices pursuant to 37 C.F.R. § 42.8(a)(3).

### **A. Real Party-in-Interest (37 C.F.R. § 42.8(b)(1))**

The real parties-in-interest are: Cipla Limited; Meda Pharmaceuticals Inc.; Meda AB; Mylan N.V.; Mylan Inc. (which is an indirect wholly owned subsidiary of Mylan N.V.); Mylan Pharmaceuticals, Inc. (which is a wholly owned subsidiary of Mylan Inc.); and Mylan Specialty L.P. (which is an indirect wholly owned subsidiary of Mylan N.V.).

### **B. Related Matters (37 C.F.R. § 42.8(b)(2))**

(1) *Meda Pharms. Inc. v. Apotex Inc.*, 14-cv-01453 (D. Del.); (2) *Meda Pharms. Inc. v. Teva Pharms.*, 15-cv-00785 (D. Del.); and (3) *Meda Pharms. Inc. v. Perrigo UK Finco Ltd.*, 16-cv-00794 (D. Del.).

Patent Owner identifies the following patent application that claims or may claim the benefit of the priority of the filing date of U.S. Patent No. 8,168,620:

- U.S. Application No. 15/070,839 filed March 15, 2016 (pending).

Patent Owner further identifies the following patent application assigned to Meda Pharmaceuticals Inc.:

- U.S. Application No. 13/284,836 filed October 28, 2011 (pending).

Patent Owner does not concede that any of these applications would affect, or be affected by, a decision in the present *inter partes* review of U.S. Patent No.

## Cipla Limited's Updated Mandatory Notices

8,168,620.

### C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3))

Patent Owner designates the following lead and back-up counsel:

Lead Counsel: Dennies Varughese (Reg. No. 61,868) phone: 202.772.8805

Back-up Counsel: Deborah A. Sterling (Reg. No. 62,732) phone: 202.772.8501

Back-up Counsel: Adam C. LaRock (Reg. No. 64,681) phone: 202.772.8794

(Pending *pro hac vice* admittance):

Back-up Counsel: Uma N. Everett phone: 202.772.8520

Address: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

1100 New York Avenue, NW

Washington, DC 20005

202.371.2600 (reception)

202.371.2540 (facsimile)

dvarughe-PTAB@skgf.com

dsterlin-PTAB@skgf.com

alarock-PTAB@skgf.com

ueverett-PTAB@skgf.com

## Cipla Limited's Updated Mandatory Notices

### D. Service Information (37 C.F.R. § 42.8(b)(4))

Please direct all correspondence regarding this proceeding to the lead counsel and back-up counsel at the addresses listed above.

Respectfully Submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Date: June 2, 2017

1100 New York Avenue, NW  
Washington, DC 20005  
(202) 772-8501

Dennies Varughese  
Lead Attorney for Patent Owner  
Registration No. 61,868

**CERTIFICATE OF SERVICE (37 C.F.R. §§ 42.6(e))**

The undersigned hereby certifies that the above-captioned “Cipla Limited’s Updated Mandatory Notices” was served in its entirety on June 2, 2017, upon the following parties via email:

Michael R. Houston: mhouston@foley.com  
Joseph P. Meara: jmeara@foley.com  
James P. McParland: jmcparland@foley.com  
ARG-dymista@foley.com

FOLEY & LARDNER LLP  
321 North Clark Street  
Suite 2800  
Chicago, IL 60654

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Date: June 2, 2017  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

---

Dennies Varughese  
Lead Attorney for Patent Owner  
Registration No. 61,868